{"prompt": "['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 1 of 92', 'CR845-CLIN3102', 'CARA', 'HERAPEUTICS', 'A MULTICENTER, DOUBLE-BLIND, RANDOMIZED,', 'PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND', 'EFFICACY OF INTRAVENOUS CR845 IN HEMODIALYSIS PATIENTS', 'WITH MODERATE-TO-SEVERE PRURITUS, WITH A 52-WEEK', 'OPEN-LABEL EXTENSION', 'Protocol number:', 'CR845-CLIN3102', 'Phase:', '3', 'IND number:', '123140', 'Protocol version:', 'Version 1.0', 'Date:', 'December 21,2017', 'Sponsor:', 'Cara Therapeutics, Inc.', '4 Stamford Plaza', 'Stamford, CT 06902', '(203) 406-3700', 'Information contained in this document is proprietary and confidential information of Cara Therapeutics,', 'Inc. Any distribution, copying, or disclosure is strictly prohibited unless such disclosure is required by', 'federal regulations or state law. Persons receiving the information in this document are hereby given notice', 'that the information is confidential and may not be further copied, distributed, disseminated or otherwise', 'disclosed to any other person without the express written authorization of Cara Therapeutics, Inc.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 3 of 95']['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 2 of 92', 'CR845-CLIN3102', 'SPONSOR APPROVAL / SIGNATURE PAGE', 'Date:', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 4 of 95']['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 3 of 92', 'CR845-CLIN3102', 'INVESTIGATOR APPROVAL STATEMENT', 'I have read and understand the protocol (CR845-CLIN3102) and I agree that this', 'document contains all ethical, legal, and scientific information necessary to conduct this', 'study. I will oversee the conduct of the study as described in the protocol and any', 'amendment(s) made to the protocol.', 'I agree to conduct the study as detailed herein and in compliance with the current', 'International Council for Harmonisation Harmonised Tripartite Guideline for Good', 'Clinical Practice E6 (R1) and United States Code Title 21 (Food and Drug', 'Administration), and applicable regulatory requirements.', 'Principal Investigator', 'Printed Name:', 'Signature:', 'Date:', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 5 of 95']\n\n###\n\n", "completion": "END"}